Analyst Price Targets — ABVX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:44 am | David Nierengarten | Wedbush | $110.00 | $132.91 | TheFly | Abivax initiated with a Neutral at Wedbush |
| January 9, 2026 1:08 pm | — | Morgan Stanley | $145.00 | $116.97 | TheFly | Abivax price target raised to $145 from $101 at Morgan Stanley |
| January 8, 2026 11:53 am | Julian Harrison | BTIG | $150.00 | $126.48 | TheFly | Abivax price target raised to $150 from $120 at BTIG |
| January 8, 2026 9:22 am | — | Oppenheimer | $131.00 | $126.48 | StreetInsider | Abivax (ABVX) Reiterated at Market Outperform by Citizens: Has Cash Runway into 4Q27 |
| December 18, 2025 1:23 pm | Yatin Suneja | Guggenheim | $175.00 | $117.24 | TheFly | Abivax price target raised to $175 from $150 at Guggenheim |
| December 16, 2025 8:40 pm | — | Piper Sandler | $142.00 | $110.98 | TheFly | Abivax price target raised to $142 from $112 at Piper Sandler |
| November 24, 2025 12:22 pm | Gregory Renza | Truist Financial | $140.00 | $119.12 | TheFly | Abivax initiated with a Buy at Truist |
| November 5, 2025 9:38 pm | — | Wolfe Research | $176.00 | $99.61 | TheFly | Abivax initiated with an Outperform at Wolfe Research |
| October 13, 2025 9:24 am | Etzer Darout | Barclays | $142.00 | $93.77 | TheFly | Abivax initiated with an Overweight at Barclays |
| October 10, 2025 10:37 am | — | Guggenheim | $150.00 | $90.61 | TheFly | Abivax price target raised, named a 'Best Idea' at Guggenheim |
Latest News for ABVX
Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the…
Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
• Abivax stock is taking a hit today. Why is ABVX stock falling?
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ABVX.
Senate Trading
No Senate trades found for ABVX.
U.S. House Trading
No House trades found for ABVX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.